SLC1A5 and neoplasm: NDRG2 promotes c-Myc degradation by inhibiting AKT activation, reduce c-Myc-mediated ASCT2 transcription, ASCT2 catabolises glutamine to supply tumor tissues and promote their progression, ultimately inhibit tumor metastasis by inhibiting glutamine transport [44].